Hester Biosciences
Ticker > Company >

Hester Biosciences share price

Hester Biosciences Ltd.

NSE: HESTERBIO BSE: 524669 SECTOR: Pharmaceuticals & Drugs  39.79 K   131   13

1807.80
+4.70 (0.26%)
NSE: Today, 10:53 AM

Price Summary

Today's High

₹ 1815

Today's Low

₹ 1794

52 Week High

₹ 3379

52 Week Low

₹ 1242.95

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 1537.87 Cr.

Enterprise Value

₹ 1666.47 Cr.

No. of Shares

0.85 Cr.

P/E

48.3

P/B

4.54

Face Value

₹ 10

Div. Yield

0.39 %

Book Value (TTM)

₹  398.6

CASH

₹ 4.96 Cr.

DEBT

₹ 133.56 Cr.

Promoter Holding

53.73 %

EPS (TTM)

₹  37.43

Sales Growth

12.27%

ROE

8.98 %

ROCE

9.26%

Profit Growth

-16.03 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Hester Biosciences Ltd.

Xester Toxcinil Inomilk Reproplus CurX Fensafe Allgone Amastic

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year12.27%
3 Year11%
5 Year10.74%

Profit Growth

1 Year-16.03%
3 Year-12.03%
5 Year-9.14%

ROE%

1 Year8.98%
3 Year12.04%
5 Year14.11%

ROCE %

1 Year9.26%
3 Year12.83%
5 Year16.3%

Debt/Equity

0.4271

Price to Cash Flow

35.92

Interest Cover Ratio

8.2123

CFO/PAT (5 Yr. Avg.)

0.934531541115415

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 53.73 0.00
Dec 2024 53.73 0.00
Sep 2024 53.73 0.00
Jun 2024 53.73 0.00
Mar 2024 53.73 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has a healthy Interest coverage ratio of 8.2123.
  • The Company has been maintaining an effective average operating margins of 26.1616850599194% in the last 5 years.
  • Company has a healthy liquidity position with current ratio of 2.0918.
  • The company has a high promoter holding of 53.73%.

 Limitations

  • The company has shown a poor profit growth of -12.0349815093369% for the Past 3 years.
  • The company has shown a poor revenue growth of 11.0044767447612% for the Past 3 years.
  • Company has contingent liabilities of 116.767 Cr.
  • The company is trading at a high PE of 48.3.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 72.87 73.47 73.5 62.83 76.67
Total Expenditure 60.46 59.97 58.77 53.81 62.97
Operating Profit 12.42 13.5 14.73 9.01 13.7
Other Income 1.2 1.06 1.35 1.3 1.06
Interest 1.31 1.13 1.4 1.59 1.25
Depreciation 2.08 2.12 2.19 2.24 2.03
Exceptional Items 0 0 0 0 0
Profit Before Tax 10.23 11.31 12.48 6.49 11.48
Tax 2.79 2.87 3.15 2.05 1.85
Profit After Tax 7.43 8.43 9.34 4.44 9.64
Adjusted EPS (Rs) 8.74 9.91 10.97 5.22 11.33

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 169.43 208.48 219.35 254 285.16
Total Expenditure 116.7 136.48 158.78 199.32 238.3
Operating Profit 52.72 71.99 60.57 54.68 46.85
Other Income 2.93 1.65 4.66 5.53 4.75
Interest 5.03 3.95 2.47 6.5 5.09
Depreciation 9.39 9.63 9.5 9.79 9.78
Exceptional Items 0 -5.28 0 0 0
Profit Before Tax 41.23 54.78 53.26 43.92 36.73
Tax 10.01 14.88 13.74 11.58 9.57
Net Profit 31.22 39.9 39.52 32.34 27.16
Adjusted EPS (Rs.) 36.7 46.9 46.45 38.02 31.93

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 8.51 8.51 8.51 8.51 8.51
Total Reserves 194.57 229.07 259.93 283.88 304.21
Borrowings 7.45 2.68 73.25 83.4 79.07
Other N/C liabilities 8.44 7.11 7.92 33.57 60.04
Current liabilities 58.22 34.65 74.84 136.47 97.72
Total Liabilities 277.19 282.02 424.44 545.82 549.55
Assets
Net Block 96.76 86.69 84.31 108.22 103.46
Capital WIP 0.87 3.29 80.22 146.14 168.11
Intangible WIP 0 0.43 1.69 2.47 3.29
Investments 40.67 43.89 64.69 64.69 64.69
Loans & Advances 11.83 5.32 24.2 6.83 4.85
Other N/C Assets 3.87 2.8 2.86 1.43 0.74
Current Assets 123.18 139.61 166.47 216.05 204.41
Total Assets 277.19 282.02 424.44 545.82 549.55
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 41.23 54.78 53.26 43.92 36.73
Adjustment 12.25 19.61 11.7 14.55 13.32
Changes in Assets & Liabilities -16.31 -19.8 -32.61 -17.05 3.79
Tax Paid -11.35 -13.49 -16.44 -8.07 -11.03
Operating Cash Flow 25.82 41.1 15.91 33.36 42.81
Investing Cash Flow -21.33 -3.72 -110.58 -71.96 -20.63
Financing Cash Flow -1.39 -41.33 94.96 41.38 -24.07
Net Cash Flow 3.1 -3.95 0.28 2.77 -1.89

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 53.73 53.73 53.73 53.73 53.73
anup chandravadan kapadia... 2.68 2.68 2.68 2.68 2.68
bela gandhi 4.71 4.71 4.71 4.71 4.71
bhupendra vithaldas gandh... 4.69 4.69 4.69 4.69 4.69
biolink healthcare limite... 2.93 2.93 2.93 2.93 2.93
hester coatings llp 0.75 0.75 0.75 0.75 0.75
hester diagnostics privat... 0.28 0.28 0.28 0.28 0.28
hetal sanjiv gandhi 0.23 0.23 0.23 0.23 0.23
nina rajiv gandhi 8.19 8.19 8.19 8.19 8.19
rajiv dinesh gandhi 10.47 10.47 10.47 10.47 10.47
ravin gandhi 4.74 4.74 4.74 4.74 4.74
sanjiv dinesh gandhi 8.20 8.20 8.20 8.20 8.20
shaila bhupendra gandhi 5.78 5.78 5.78 5.78 5.78
yash rajiv gandhi 0.09 0.09 0.09 0.09 0.09
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 46.27 46.27 46.27 46.27 46.27
darshna dinesh kapadia 1.81 1.81 1.81 1.81 1.81
investor education and pr... - 0.96 0.96 1.00 0.99
jagrut prataprai gandhi 1.18 1.18 1.18 1.18 1.18
kuntal hasmukhlal shah 3.07 3.07 3.07 3.07 3.17
llp 0.17 0.19 0.12 0.12 0.34
manish jain 2.88 2.88 2.88 4.06 4.11
manish prataprai gandhi 1.18 1.18 1.18 1.18 1.18
sandeep shantilal gala - 1.12 1.15 1.15 1.06
vinay shah 1.28 1.28 1.28 1.28 1.28
investor education and pr... 0.96 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CARE
Credit CARE
Credit CARE
Credit CARE
Credit CARE RATINGS
Credit CARE
TYPE AGENCY Link
TYPE AGENCY Link
Research ICICI Securities Limited

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY21
Concall Q3FY25
Concall Q3FY24
Concall Q1FY25
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY19

Company News

Hester Biosciences informs about newspaper publication 10 May, 11:34 AM Hester Biosciences informs about outcome of board meeting 9 May, 2:33 PM Hester Biosciences informs about outcome of board meeting 9 May, 2:07 PM Hester Biosciences informs about outcome of board meeting 9 May, 12:44 PM Hester Biosciences - Quaterly Results 9 May, 11:51 AM Hester Biosciences - Quaterly Results 9 May, 11:51 AM Hester Biosciences - Quaterly Results 9 May, 11:51 AM Hester Biosciences informs about board meeting 2 May, 11:29 AM Hester Biosciences informs about clarification 26 Apr, 1:56 PM Hester Biosciences informs about confirmation certificate 8 Apr, 2:09 PM Hester Biosciences informs about trading window closure 26 Mar, 12:22 PM Hester Biosciences - Quaterly Results 30 Jan, 12:05 PM Hester Biosciences - Quaterly Results 30 Jan, 12:05 PM Hester Biosciences - Quaterly Results 30 Jan, 12:05 PM Hester Biosciences informs about earnings conference call 23 Jan, 5:21 PM Hester Biosciences informs about board meeting 22 Jan, 4:56 PM Hester Biosciences informs about newspaper clipping 14 Jan, 9:45 AM Hester Biosciences informs about certificate 6 Jan, 10:26 AM Hester Biosciences informs about credit rating 20 Dec, 2:12 PM Hester Biosciences informs about outcome of board meeting 28 Oct, 12:49 PM Hester Biosciences - Quaterly Results 28 Oct, 12:27 PM Hester Biosciences - Quaterly Results 28 Oct, 12:27 PM Hester Biosciences - Quaterly Results 28 Oct, 12:27 PM Hester Biosciences informs about details of loss of certificate 7 Oct, 4:47 PM Hester Biosciences submits analyst meet outcome 5 Aug, 4:27 PM Hester Biosciences informs about newspaper clippings 5 Aug, 11:40 AM Hester Biosciences informs about outcome of board meeting 2 Aug, 4:50 PM Hester Biosciences - Quaterly Results 2 Aug, 11:19 AM Hester Biosciences - Quaterly Results 2 Aug, 11:19 AM Hester Biosciences - Quaterly Results 2 Aug, 11:19 AM Hester Biosciences informs about newspaper clipping 27 Jul, 12:16 PM Hester Biosciences informs about earnings call 27 Jul, 10:05 AM Hester Biosciences informs about AGM and annual report 26 Jul, 5:23 PM Hester Biosciences informs about loss of share certificates 3 Jul, 11:40 AM Hester Biosciences informs about compliance report 16 May, 12:01 PM Hester Biosciences - Quaterly Results 10 May, 12:32 PM Hester Biosciences - Quaterly Results 10 May, 12:32 PM Hester Biosciences - Quaterly Results 10 May, 12:32 PM Hester Biosciences informs about earnings call 8 May, 10:25 AM Hester Biosciences informs about revised certificate 9 Apr, 2:18 PM Hester Biosciences informs about compliance certificate 4 Apr, 1:23 PM Hester Biosciences informs about outcome of board meeting 2 Feb, 12:33 PM Hester Biosciences - Quaterly Results 2 Feb, 12:24 PM Hester Biosciences - Quaterly Results 2 Feb, 12:24 PM Hester Biosciences - Quaterly Results 2 Feb, 12:24 PM Hester Biosciences informs about disclosure 30 Jan, 5:11 PM Hester Biosciences informs about disclosure 30 Jan, 5:07 PM Hester Biosciences informs about board meeting 24 Jan, 5:08 PM Hester Biosciences informs about certificate 8 Jan, 5:26 PM Hester Biosciences informs about credit ratings 2 Jan, 5:14 PM

Hester Biosciences Stock Price Analysis and Quick Research Report. Is Hester Biosciences an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Hester Biosciences and its performance over the period of time. Hester Biosciences stock price today is Rs 1807.8.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Hester Biosciences cash from the operating activity was Rs 42.812 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Hester Biosciences has a Debt to Equity ratio of 0.4271 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Hester Biosciences , the EPS growth was -16.0255 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Hester Biosciences has OPM of 16.4300117479967 % which is a good sign for profitability.
     
  • ROE: Hester Biosciences have a poor ROE of 8.9768 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Hester Biosciences is Rs 1807.8. One can use valuation calculators of ticker to know if Hester Biosciences share price is undervalued or overvalued.
Last Updated on:
Brief about Hester Biosciences

Hester Biosciences Limited Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Hester Biosciences Limited is a leading biotechnology company specializing in the manufacturing and marketing of vaccines, diagnostics, and related products for animal health. Established in 1987, Hester Biosciences has emerged as a trusted name in the veterinary pharmaceutical industry. With a focus on research and innovation, the company is committed to enhancing animal health and well-being through its high-quality products.

Hester Biosciences Limited :  Share Price

Stay up-to-date with the latest share price of Hester Biosciences Limited by visiting our stock analysis page. Our user-friendly interface allows investors to track the performance of Hester Biosciences in real-time. Analyze historical prices, monitor market trends, and make informed investment decisions using our pre-built screening tools.

Hester Biosciences Limited :  Balance Sheet

Evaluate the financial health of Hester Biosciences Limited by examining its balance sheet. Our website provides access to downloadable annual reports, offering a detailed overview of the company's assets, liabilities, and shareholder equity. Utilize our premium features, such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis, to calculate the fair value of the stock and determine its potential long-term growth.

Hester Biosciences Limited : Annual Report

Gain valuable insights into Hester Biosciences Limited's performance, strategies, and future prospects by accessing the annual reports available for download on our website. Explore the company's achievements, challenges, and financial highlights recorded over the year. Stay informed of key developments and make well-informed decisions based on comprehensive information provided in these reports.

Hester Biosciences Limited :  Dividend

Investors seeking consistent income streams through dividends can keep track of Hester Biosciences Limited's dividend payments. Stay updated with the company's dividend history, payout ratios, and dividend yield on our stock analysis page. Our website provides a convenient platform to monitor dividend trends and assess the company's commitment to rewarding its shareholders.

Hester Biosciences Limited  : Quarterly Results

Monitor Hester Biosciences Limited's financial performance on a quarterly basis by accessing our website's quarterly result section. Download the latest financial statements to analyze revenue, expenses, and profitability indicators. Utilize our premium tools to calculate the fair value of the stock and understand its potential for long-term growth.

Hester Biosciences Limited :  Stock Price Chart

Track the historical movements of Hester Biosciences Limited's stock price through our user-friendly stock price chart. Our website's interactive charts allow investors to analyze price trends, identify patterns, and make informed decisions. Combine technical analysis with fundamental analysis to enhance your understanding of the company's stock performance.

Hester Biosciences Limited :  News

Stay updated with the latest news and developments related to Hester Biosciences Limited on our stock analysis page. Access news articles, press releases, and industry updates to stay informed of key events that may impact the company's performance and stock price. Make informed investment decisions based on current market information.

Hester Biosciences Limited : Concall Transcripts

Access Hester Biosciences Limited's concall transcripts on our website. By reading these transcripts, investors can gain insights into management discussions, future strategies, and industry trends. Stay informed of key announcements and decisions made during the company's earnings calls.

Hester Biosciences Limited : Investor Presentations

Explore Hester Biosciences Limited's investor presentations, available for download on our website. These presentations provide an in-depth understanding of the company's operations, growth strategies, and future plans. Stay updated with the latest developments and assess the company's potential for long-term value creation.

Hester Biosciences Limited : Promoters

Hester Biosciences Limited's promoters play a crucial role in the company's growth and success. Gain insights into the promoters' background, contributions, and strategic involvement in the company's operations. Understand the promoter's vision and commitment to the company's long-term goals.

Hester Biosciences Limited :  Shareholders

Discover the major shareholders of Hester Biosciences Limited on our stock analysis page. Identify institutional investors, mutual funds, and other major stakeholders who hold significant positions in the company. Analyze the shareholder composition to gauge market sentiment and understand the company's appeal to long-term investors.

At our website, we provide a comprehensive platform for long-term stock investors seeking in-depth stock analysis. With our pre-built screening tools and premium features, investors can access a wide range of information including balance sheets, quarterly results, profit and loss statements, annual reports, concall transcripts, investor presentations, credit ratings, and research reports. Empower yourself with the necessary information to make well-informed investment decisions. 

Hester Biosciences Share Capital Consistency

Hester Biosciences + Solid Share Capital

Hester Biosciences has consistently displayed a steady share capital of Rs 8.51 Cr from March 2020 to March 2024, indicating a stable equity base without additional equity dilution during this period.

Hester Biosciences + Increasing Reserves

The company's total reserves have shown a robust increase from Rs 194.57 Cr in March 2020 to Rs 304.21 Cr in March 2024. This growth in reserves is a positive sign, reflecting Hester Biosciences' potential to reinvest in its operations and future growth.

Hester Biosciences + Borrowings and Liabilities

An observation of interest is the fluctuation in borrowings, with a substantial rise noted from Rs 7.45 Cr in March 2020 to Rs 83.40 Cr in March 2023, before a slight reduction to Rs 79.07 Cr by March 2024. Other non-current liabilities and current liabilities also saw variations, potentially due to short-term financial strategy changes.

Hester Biosciences + Asset Evolution

Over the same period, Hester Biosciences' total assets expanded from Rs 277.19 Cr to Rs 549.55 Cr, with current assets and capital work in progress (Capital WIP) experiencing significant growth - a move that might align with the company's strategic investments and development projects.

This data presents an analysis for the Standalone Balance Sheet of Hester Biosciences.

In the dynamic atmosphere of the stock market, investors might consider factors such as Hester Biosciences' asset management when screening stocks for portfolio inclusion.

Read More
X